[HTML][HTML] Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer
RK Murthy, S Loi, A Okines, E Paplomata… - … England Journal of …, 2020 - Mass Medical Soc
Background Patients with human epidermal growth factor receptor 2 (HER2)–positive
metastatic breast cancer who have disease progression after therapy with multiple HER2-targeted …
metastatic breast cancer who have disease progression after therapy with multiple HER2-targeted …
[HTML][HTML] Intracranial efficacy and survival with tucatinib plus trastuzumab and capecitabine for previously treated HER2-positive breast cancer with brain metastases in …
PURPOSE In the HER2CLIMB study, patients with human epidermal growth factor receptor
2 (HER2)–positive breast cancer with brain metastases (BMs) showed statistically significant …
2 (HER2)–positive breast cancer with brain metastases (BMs) showed statistically significant …
[HTML][HTML] Antitumor activity and safety of trastuzumab deruxtecan in patients with HER2-low–expressing advanced breast cancer: results from a phase Ib study
S Modi, H Park, RK Murthy, H Iwata… - Journal of Clinical …, 2020 - ncbi.nlm.nih.gov
PURPOSE Trastuzumab deruxtecan (T-DXd, formerly DS-8201a) is a novel human
epidermal growth factor receptor 2 (HER2)-targeted antibody drug conjugate (ADC) with a …
epidermal growth factor receptor 2 (HER2)-targeted antibody drug conjugate (ADC) with a …
[HTML][HTML] Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients
…, P Mhawech-Fauceglia, SL Moulder, RK Murthy… - The Lancet …, 2022 - thelancet.com
Background Previous studies have independently validated the prognostic relevance of
residual cancer burden (RCB) after neoadjuvant chemotherapy. We used results from several …
residual cancer burden (RCB) after neoadjuvant chemotherapy. We used results from several …
Tucatinib with capecitabine and trastuzumab in advanced HER2-positive metastatic breast cancer with and without brain metastases: a non-randomised, open-label …
R Murthy, VF Borges, A Conlin, J Chaves… - The lancet …, 2018 - thelancet.com
Background Tucatinib is a potent and selective oral HER2 tyrosine kinase inhibitor, with the
potential to provide a well tolerated new treatment option for patients whose disease has …
potential to provide a well tolerated new treatment option for patients whose disease has …
[HTML][HTML] Outcomes of children exposed in uteroto chemotherapy for breast cancer
RK Murthy, RL Theriault, CM Barnett, S Hodge… - Breast Cancer …, 2014 - Springer
Introduction The incidence of breast cancer diagnosed during pregnancy is expected to
increase as more women delay childbearing in the United States. Treatment of cancer in …
increase as more women delay childbearing in the United States. Treatment of cancer in …
Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion …
Background Trastuzumab deruxtecan (DS-8201a) is a novel HER2-targeted antibody–drug
conjugate with a humanised anti-HER2 antibody, cleavable peptide-based linker, and potent …
conjugate with a humanised anti-HER2 antibody, cleavable peptide-based linker, and potent …
Advances in HER2-targeted therapy: novel agents and opportunities beyond breast and gastric cancer
…, K Raghav, K Balaji, M Bhatt, RK Murthy… - Clinical Cancer …, 2019 - AACR
The introduction of HER2-targeted therapy for breast and gastric patients with ERBB2 (HER2)
amplification/overexpression has led to dramatic improvements in oncologic outcomes. In …
amplification/overexpression has led to dramatic improvements in oncologic outcomes. In …
Tucatinib vs placebo, both in combination with trastuzumab and capecitabine, for previously treated ERBB2 (HER2)-positive metastatic breast cancer in patients with …
Importance It is estimated that up to 50% of patients with ERBB2 (HER2)-positive metastatic
breast cancer (MBC) will develop brain metastases (BMs), which is associated with poor …
breast cancer (MBC) will develop brain metastases (BMs), which is associated with poor …
Targeting the PI3K/AKT/mTOR pathway for the treatment of mesenchymal triple-negative breast cancer: evidence from a phase 1 trial of mTOR inhibition in …
RK Basho, M Gilcrease, RK Murthy, T Helgason… - JAMA …, 2017 - jamanetwork.com
Importance Triple-negative breast cancer (TNBC) classified by transcriptional profiling as
the mesenchymal subtype frequently harbors aberrations in the phosphoinositide 3-kinase (…
the mesenchymal subtype frequently harbors aberrations in the phosphoinositide 3-kinase (…